Helixgate

Helixgate

Uncategorized

GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts

Published

on

GSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels said during its first-quarter earnings call with the media Wednesday.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

What is your AI drug repurposing strategy missing?

Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.

Read More

Published

on

Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.

Read More

Continue Reading

Uncategorized

Opinion: Are blue zones real? Answering that question is harder than ever

When French geneticist Jean-Francois Deleuze first launched the AGENOMICS study in 2022, he hoped to identify genetic patterns among 1,200 French citizens who’d lived more than 100 years and to compare those to centenarians hailing from one of the world-famous “blue zones.”

Then he started having doubts.

Read the rest…

Read More

Published

on

When French geneticist Jean-Francois Deleuze first launched the AGENOMICS study in 2022, he hoped to identify genetic patterns among 1,200 French citizens who’d lived more than 100 years and to compare those to centenarians hailing from one of the world-famous “blue zones.”

Then he started having doubts.

Read the rest…

Read More

Continue Reading

Uncategorized

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate

Published

on

The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.

Continue Reading
Advertisement

Trending